Concepts (340)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 20 | 2025 | 469 | 4.610 |
Why?
|
| Aging | 15 | 2023 | 938 | 3.490 |
Why?
|
| Obesity | 13 | 2026 | 1152 | 3.230 |
Why?
|
| Animals | 72 | 2026 | 7569 | 3.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 6 | 2017 | 20 | 2.580 |
Why?
|
| Subcutaneous Fat | 4 | 2026 | 49 | 2.420 |
Why?
|
| Fatty Liver | 5 | 2024 | 66 | 2.400 |
Why?
|
| Liver | 11 | 2021 | 492 | 2.300 |
Why?
|
| Muscle, Skeletal | 8 | 2025 | 524 | 2.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2025 | 1462 | 2.030 |
Why?
|
| Fructose | 6 | 2021 | 12 | 1.840 |
Why?
|
| Adipose Tissue | 6 | 2023 | 349 | 1.740 |
Why?
|
| Endotoxemia | 4 | 2016 | 7 | 1.730 |
Why?
|
| Whole-Body Irradiation | 5 | 2025 | 55 | 1.600 |
Why?
|
| Blood Glucose | 14 | 2020 | 494 | 1.540 |
Why?
|
| Macaca mulatta | 9 | 2026 | 318 | 1.240 |
Why?
|
| Mitochondria | 2 | 2025 | 206 | 1.230 |
Why?
|
| Primates | 9 | 2023 | 116 | 1.220 |
Why?
|
| Intra-Abdominal Fat | 3 | 2026 | 63 | 1.210 |
Why?
|
| Adipocytes | 4 | 2025 | 84 | 1.160 |
Why?
|
| Feces | 2 | 2025 | 43 | 1.120 |
Why?
|
| Inflammation | 5 | 2023 | 536 | 1.090 |
Why?
|
| Female | 37 | 2026 | 20261 | 1.080 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 243 | 1.050 |
Why?
|
| Glucose | 4 | 2017 | 184 | 1.050 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2023 | 57 | 1.030 |
Why?
|
| Prediabetic State | 3 | 2020 | 72 | 0.990 |
Why?
|
| Adipose Tissue, Brown | 2 | 2023 | 8 | 0.980 |
Why?
|
| Longevity | 2 | 2025 | 21 | 0.980 |
Why?
|
| Male | 33 | 2026 | 19641 | 0.980 |
Why?
|
| Intestinal Mucosa | 2 | 2017 | 73 | 0.970 |
Why?
|
| Motor Activity | 2 | 2019 | 327 | 0.940 |
Why?
|
| Muscle Proteins | 1 | 2025 | 63 | 0.930 |
Why?
|
| Mitochondrial Size | 1 | 2025 | 1 | 0.910 |
Why?
|
| T-Lymphocytes | 1 | 2026 | 129 | 0.900 |
Why?
|
| Signal Transduction | 3 | 2026 | 686 | 0.900 |
Why?
|
| Insulin | 9 | 2014 | 367 | 0.810 |
Why?
|
| Quercetin | 1 | 2023 | 8 | 0.810 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2023 | 6 | 0.790 |
Why?
|
| Lipids | 9 | 2022 | 229 | 0.700 |
Why?
|
| Lipoproteins, HDL | 2 | 2022 | 252 | 0.670 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2020 | 43 | 0.670 |
Why?
|
| Quadriceps Muscle | 1 | 2020 | 32 | 0.660 |
Why?
|
| Energy Metabolism | 2 | 2025 | 155 | 0.660 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 1012 | 0.650 |
Why?
|
| Body Composition | 7 | 2022 | 388 | 0.650 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 82 | 0.650 |
Why?
|
| Macaca fascicularis | 11 | 2017 | 431 | 0.640 |
Why?
|
| Haplorhini | 6 | 2018 | 69 | 0.610 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 37 | 0.600 |
Why?
|
| Trans Fatty Acids | 2 | 2010 | 10 | 0.600 |
Why?
|
| Bacterial Infections | 1 | 2019 | 51 | 0.600 |
Why?
|
| Microvessels | 2 | 2026 | 28 | 0.590 |
Why?
|
| Amniotic Fluid | 1 | 2019 | 86 | 0.590 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 18 | 0.570 |
Why?
|
| Bacteria | 1 | 2018 | 55 | 0.550 |
Why?
|
| Mobility Limitation | 1 | 2019 | 220 | 0.550 |
Why?
|
| Medicago sativa | 1 | 2017 | 1 | 0.540 |
Why?
|
| Mice | 9 | 2024 | 2511 | 0.530 |
Why?
|
| Body Weight | 10 | 2016 | 301 | 0.530 |
Why?
|
| Exercise Therapy | 1 | 2019 | 271 | 0.520 |
Why?
|
| Hot Temperature | 2 | 2019 | 78 | 0.520 |
Why?
|
| Gastrointestinal Motility | 1 | 2017 | 3 | 0.520 |
Why?
|
| Tight Junctions | 1 | 2017 | 10 | 0.520 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 789 | 0.520 |
Why?
|
| Hydrotherapy | 1 | 2016 | 4 | 0.500 |
Why?
|
| Monkey Diseases | 3 | 2011 | 20 | 0.480 |
Why?
|
| Muscles | 1 | 2016 | 63 | 0.480 |
Why?
|
| Sarcopenia | 1 | 2016 | 66 | 0.460 |
Why?
|
| Glucose Tolerance Test | 8 | 2016 | 125 | 0.460 |
Why?
|
| Hypoglycemic Agents | 4 | 2011 | 180 | 0.450 |
Why?
|
| Hypertension | 1 | 2022 | 976 | 0.450 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 1140 | 0.440 |
Why?
|
| Physical Endurance | 1 | 2014 | 35 | 0.430 |
Why?
|
| Diet | 5 | 2024 | 390 | 0.430 |
Why?
|
| Glucose Intolerance | 2 | 2011 | 46 | 0.420 |
Why?
|
| Muscle Strength | 1 | 2014 | 157 | 0.410 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2019 | 82 | 0.400 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2013 | 15 | 0.400 |
Why?
|
| Echium | 1 | 2013 | 11 | 0.400 |
Why?
|
| gamma-Linolenic Acid | 1 | 2013 | 10 | 0.400 |
Why?
|
| Plant Oils | 1 | 2013 | 17 | 0.400 |
Why?
|
| Pregnancy | 6 | 2026 | 981 | 0.390 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 57 | 0.390 |
Why?
|
| Pregnancy Complications | 2 | 2011 | 111 | 0.370 |
Why?
|
| Streptozocin | 2 | 2011 | 8 | 0.370 |
Why?
|
| Fibrosis | 3 | 2023 | 122 | 0.360 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2009 | 138 | 0.360 |
Why?
|
| Proteomics | 2 | 2025 | 97 | 0.350 |
Why?
|
| Overweight | 1 | 2013 | 263 | 0.350 |
Why?
|
| Weight Gain | 2 | 2013 | 112 | 0.350 |
Why?
|
| Cercopithecus aethiops | 1 | 2011 | 1 | 0.350 |
Why?
|
| Isoflavones | 2 | 2008 | 79 | 0.340 |
Why?
|
| Stillbirth | 1 | 2011 | 13 | 0.340 |
Why?
|
| Soybean Proteins | 2 | 2008 | 77 | 0.340 |
Why?
|
| Dietary Fats | 2 | 2011 | 109 | 0.330 |
Why?
|
| Growth | 1 | 2010 | 6 | 0.330 |
Why?
|
| Growth Disorders | 1 | 2010 | 5 | 0.330 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2025 | 59 | 0.320 |
Why?
|
| Hyperglycemia | 4 | 2011 | 81 | 0.320 |
Why?
|
| Fluid Shifts | 1 | 2010 | 2 | 0.320 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2026 | 44 | 0.320 |
Why?
|
| PPAR gamma | 1 | 2010 | 44 | 0.320 |
Why?
|
| Thiazolidinediones | 1 | 2010 | 45 | 0.320 |
Why?
|
| Heat-Shock Proteins | 2 | 2014 | 33 | 0.310 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2009 | 11 | 0.310 |
Why?
|
| Menopause | 2 | 2013 | 97 | 0.310 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 90 | 0.310 |
Why?
|
| Adiponectin | 5 | 2017 | 103 | 0.300 |
Why?
|
| Cytokines | 2 | 2022 | 247 | 0.290 |
Why?
|
| Macrophages | 2 | 2022 | 194 | 0.290 |
Why?
|
| Hyperinsulinism | 1 | 2008 | 13 | 0.290 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2008 | 23 | 0.280 |
Why?
|
| Phytotherapy | 1 | 2008 | 37 | 0.280 |
Why?
|
| Soybeans | 1 | 2008 | 35 | 0.280 |
Why?
|
| Plant Extracts | 1 | 2008 | 61 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2011 | 622 | 0.260 |
Why?
|
| Atherosclerosis | 2 | 2011 | 788 | 0.260 |
Why?
|
| Cholesterol, HDL | 2 | 2022 | 175 | 0.250 |
Why?
|
| Placental Circulation | 1 | 2026 | 2 | 0.240 |
Why?
|
| Insulin-Secreting Cells | 3 | 2011 | 53 | 0.240 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2026 | 32 | 0.240 |
Why?
|
| Animal Feed | 3 | 2019 | 17 | 0.240 |
Why?
|
| Carbohydrates | 1 | 2005 | 8 | 0.240 |
Why?
|
| Hormones | 1 | 2005 | 20 | 0.230 |
Why?
|
| Phenotype | 3 | 2022 | 638 | 0.230 |
Why?
|
| Diet, Fat-Restricted | 2 | 2017 | 31 | 0.230 |
Why?
|
| Placenta | 1 | 2026 | 75 | 0.230 |
Why?
|
| Iron | 2 | 2019 | 116 | 0.230 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2024 | 10 | 0.220 |
Why?
|
| Middle Aged | 5 | 2023 | 12125 | 0.210 |
Why?
|
| Homeostasis | 2 | 2015 | 135 | 0.210 |
Why?
|
| Humans | 12 | 2023 | 32798 | 0.210 |
Why?
|
| Endpoint Determination | 3 | 2013 | 20 | 0.200 |
Why?
|
| Myocardium | 3 | 2023 | 191 | 0.200 |
Why?
|
| Cholesterol, Dietary | 2 | 2014 | 36 | 0.200 |
Why?
|
| Thermogenesis | 1 | 2023 | 5 | 0.200 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2023 | 25 | 0.200 |
Why?
|
| Diterpenes | 2 | 2014 | 17 | 0.200 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 475 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 24 | 0.190 |
Why?
|
| Aged | 4 | 2023 | 10538 | 0.190 |
Why?
|
| Biopsy | 1 | 2023 | 245 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 66 | 0.190 |
Why?
|
| Fatty Acids | 1 | 2022 | 99 | 0.180 |
Why?
|
| Sirtuins | 1 | 2021 | 21 | 0.180 |
Why?
|
| Collagen | 1 | 2022 | 219 | 0.180 |
Why?
|
| Gene Expression | 1 | 2022 | 334 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2022 | 136 | 0.180 |
Why?
|
| Lipid Metabolism | 2 | 2013 | 105 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 307 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2022 | 197 | 0.170 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 227 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2022 | 116 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 422 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 107 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 44 | 0.170 |
Why?
|
| Animals, Newborn | 2 | 2011 | 119 | 0.160 |
Why?
|
| Peanut Hypersensitivity | 1 | 2020 | 2 | 0.160 |
Why?
|
| Allergens | 1 | 2020 | 15 | 0.160 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 55 | 0.160 |
Why?
|
| Immunoglobulin E | 1 | 2020 | 36 | 0.160 |
Why?
|
| Energy Intake | 2 | 2013 | 128 | 0.160 |
Why?
|
| Lipolysis | 1 | 2019 | 17 | 0.160 |
Why?
|
| Iron, Dietary | 1 | 2019 | 13 | 0.160 |
Why?
|
| Weight Loss | 3 | 2019 | 457 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 128 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2022 | 908 | 0.150 |
Why?
|
| Pancreas | 2 | 2011 | 103 | 0.150 |
Why?
|
| Risk Factors | 2 | 2022 | 3974 | 0.150 |
Why?
|
| Adiposity | 2 | 2010 | 198 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2018 | 13 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 58 | 0.140 |
Why?
|
| Cattle | 1 | 2018 | 108 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2016 | 92 | 0.140 |
Why?
|
| Colon | 1 | 2018 | 51 | 0.140 |
Why?
|
| Fasting | 2 | 2016 | 94 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 27 | 0.140 |
Why?
|
| Stress, Physiological | 2 | 2017 | 54 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 31 | 0.130 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 99 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 47 | 0.130 |
Why?
|
| Macrophage Activation | 1 | 2017 | 11 | 0.130 |
Why?
|
| Bacteriuria | 1 | 2017 | 4 | 0.130 |
Why?
|
| Copper | 1 | 2017 | 11 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2017 | 84 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 25 | 0.130 |
Why?
|
| Urinary Tract | 1 | 2017 | 22 | 0.130 |
Why?
|
| Time Factors | 3 | 2020 | 2183 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2022 | 226 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2017 | 78 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 163 | 0.130 |
Why?
|
| Bacterial Translocation | 1 | 2016 | 9 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2016 | 25 | 0.120 |
Why?
|
| Intestines | 1 | 2016 | 60 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2016 | 46 | 0.120 |
Why?
|
| Pedigree | 2 | 2013 | 140 | 0.120 |
Why?
|
| Heart | 1 | 2016 | 185 | 0.110 |
Why?
|
| Triglycerides | 3 | 2010 | 228 | 0.110 |
Why?
|
| Microcirculation | 2 | 2026 | 64 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2284 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 315 | 0.110 |
Why?
|
| Lipoproteins | 2 | 2014 | 86 | 0.100 |
Why?
|
| Random Allocation | 1 | 2014 | 229 | 0.100 |
Why?
|
| Contrast Media | 2 | 2026 | 138 | 0.100 |
Why?
|
| Metagenome | 1 | 2013 | 5 | 0.100 |
Why?
|
| Models, Animal | 1 | 2014 | 171 | 0.100 |
Why?
|
| Lipoproteins, LDL | 2 | 2013 | 80 | 0.100 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2013 | 37 | 0.100 |
Why?
|
| Cercopithecinae | 1 | 2013 | 2 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2013 | 48 | 0.100 |
Why?
|
| Perfusion | 2 | 2022 | 74 | 0.100 |
Why?
|
| Sex Factors | 2 | 2013 | 675 | 0.100 |
Why?
|
| Piperidines | 2 | 2010 | 120 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2026 | 381 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 241 | 0.090 |
Why?
|
| Women's Health | 1 | 2013 | 235 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3701 | 0.090 |
Why?
|
| Genotype | 1 | 2013 | 731 | 0.090 |
Why?
|
| Hemoglobin A, Glycosylated | 1 | 2011 | 1 | 0.090 |
Why?
|
| Arginine | 1 | 2011 | 18 | 0.090 |
Why?
|
| Fetal Macrosomia | 1 | 2011 | 6 | 0.090 |
Why?
|
| Superoxides | 1 | 2011 | 19 | 0.090 |
Why?
|
| Heat Stress Disorders | 1 | 2011 | 11 | 0.090 |
Why?
|
| Hierarchy, Social | 1 | 2011 | 25 | 0.080 |
Why?
|
| Fetal Development | 1 | 2011 | 27 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2011 | 27 | 0.080 |
Why?
|
| Triazines | 1 | 2010 | 3 | 0.080 |
Why?
|
| Arteries | 1 | 2011 | 71 | 0.080 |
Why?
|
| Azetidines | 1 | 2010 | 10 | 0.080 |
Why?
|
| Gestational Age | 1 | 2011 | 129 | 0.080 |
Why?
|
| Anti-Obesity Agents | 1 | 2010 | 9 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 91 | 0.080 |
Why?
|
| Lactation | 1 | 2010 | 16 | 0.080 |
Why?
|
| Milk, Human | 1 | 2010 | 17 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 142 | 0.080 |
Why?
|
| Body Water | 1 | 2010 | 8 | 0.080 |
Why?
|
| Propionates | 1 | 2010 | 4 | 0.080 |
Why?
|
| Extracellular Fluid | 1 | 2010 | 10 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 25 | 0.080 |
Why?
|
| Abdominal Fat | 1 | 2010 | 47 | 0.080 |
Why?
|
| C-Peptide | 2 | 2011 | 30 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 459 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 57 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2011 | 176 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 83 | 0.080 |
Why?
|
| PPAR alpha | 1 | 2010 | 29 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 136 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2010 | 76 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 947 | 0.070 |
Why?
|
| Apoptosis | 1 | 2011 | 362 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1163 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 58 | 0.070 |
Why?
|
| Seeds | 1 | 2008 | 11 | 0.070 |
Why?
|
| Thyroxine | 1 | 2008 | 16 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 167 | 0.070 |
Why?
|
| Premenopause | 1 | 2008 | 44 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 288 | 0.070 |
Why?
|
| Body Size | 1 | 2007 | 34 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2007 | 100 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2007 | 172 | 0.060 |
Why?
|
| African Americans | 1 | 2013 | 1424 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 195 | 0.060 |
Why?
|
| Fructosamine | 1 | 2005 | 5 | 0.060 |
Why?
|
| Androstenedione | 1 | 2005 | 5 | 0.060 |
Why?
|
| Estrone | 1 | 2005 | 8 | 0.060 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2005 | 8 | 0.060 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 28 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 126 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 61 | 0.060 |
Why?
|
| Age Factors | 1 | 2008 | 1197 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2005 | 162 | 0.060 |
Why?
|
| Estradiol | 1 | 2005 | 121 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 154 | 0.050 |
Why?
|
| Substance P | 1 | 2023 | 21 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2023 | 42 | 0.050 |
Why?
|
| Xenon | 1 | 2022 | 3 | 0.050 |
Why?
|
| Lactobacillus acidophilus | 1 | 2022 | 1 | 0.050 |
Why?
|
| Diastole | 1 | 2022 | 97 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2022 | 59 | 0.050 |
Why?
|
| Mammals | 1 | 2021 | 13 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 252 | 0.040 |
Why?
|
| Maternal Age | 1 | 2020 | 14 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 144 | 0.040 |
Why?
|
| Histamine | 1 | 2020 | 3 | 0.040 |
Why?
|
| Anaphylaxis | 1 | 2020 | 12 | 0.040 |
Why?
|
| Teichoic Acids | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cell Wall | 1 | 2019 | 7 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 370 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 20 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 28 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 115 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 497 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 520 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 214 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 32 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 40 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 594 | 0.030 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 5 | 0.030 |
Why?
|
| Ions | 1 | 2017 | 12 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 133 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2020 | 862 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 551 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 29 | 0.030 |
Why?
|
| Cell Size | 1 | 2014 | 36 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 80 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 19 | 0.030 |
Why?
|
| Fever | 1 | 2014 | 60 | 0.030 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2013 | 9 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 253 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 636 | 0.020 |
Why?
|
| Catalase | 1 | 2011 | 15 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 42 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2011 | 61 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 94 | 0.020 |
Why?
|
| Ferritins | 1 | 2011 | 48 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 152 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 120 | 0.020 |
Why?
|
| Amyloidosis | 1 | 2010 | 16 | 0.020 |
Why?
|
| Leptin | 1 | 2010 | 73 | 0.020 |
Why?
|
| Eating | 1 | 2010 | 74 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Fluorobenzenes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2011 | 239 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 158 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 238 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 237 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 3 | 0.020 |
Why?
|
| Exercise | 1 | 2014 | 679 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 64 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 754 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1606 | 0.020 |
Why?
|
| Cercopithecidae | 1 | 2006 | 10 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2005 | 10 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2005 | 114 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 470 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 511 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 4032 | 0.010 |
Why?
|
| Adult | 1 | 2005 | 9560 | 0.010 |
Why?
|